Indibulin

Generic Name
Indibulin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H16ClN3O2
CAS Number
204205-90-3
Unique Ingredient Identifier
80K4H2RB8P
Indication

Investigated for use/treatment in solid tumors.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer

Phase 1
Conditions
Metastatic Breast Cancer
Interventions
Drug: Indibulin
First Posted Date
2010-04-30
Last Posted Date
2013-01-30
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
60
Registration Number
NCT01113970
Locations
🇺🇸

The West Clinic, Memphis, Tennessee, United States

🇺🇸

Evergreen Hematology Oncology, Spokane, Washington, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 1 locations

Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

First Posted Date
2008-08-01
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
7
Registration Number
NCT00726687

Phase I Study of Indibulin in Patients With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: indibulin
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
47
Registration Number
NCT00591136

Phase I Study in Advanced Solid Tumors

Phase 1
Conditions
Solid Tumors
Interventions
Drug: indibulin
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
22
Registration Number
NCT00591292

Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
Drug: indibulin
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
20
Registration Number
NCT00591890

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
10
Registration Number
NCT00591383
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy